COMPASS Pathways plc (NASDAQ:CMPS) was the recipient of a large decline in short interest during the month of August. As of August 31st, there was short interest totalling 406,900 shares, a decline of 35.3% from the August 15th total of 629,200 shares. Based on an average daily volume of 386,400 shares, the short-interest ratio is presently 1.1 days.
Shares of CMPS traded down $1.77 during mid-day trading on Monday, hitting $31.37. The company had a trading volume of 382,089 shares, compared to its average volume of 409,798. COMPASS Pathways has a 1-year low of $25.66 and a 1-year high of $61.69. The business’s 50-day simple moving average is $33.52 and its 200-day simple moving average is $35.43. The stock has a market cap of $1.31 billion and a PE ratio of -12.02.
COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Tuesday, August 10th. The company reported ($0.44) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.11). Research analysts forecast that COMPASS Pathways will post -1.87 earnings per share for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of CMPS. BDO Wealth Advisors LLC raised its position in shares of COMPASS Pathways by 270.0% in the 2nd quarter. BDO Wealth Advisors LLC now owns 2,035 shares of the company’s stock valued at $78,000 after purchasing an additional 1,485 shares in the last quarter. Marshall Wace LLP bought a new position in COMPASS Pathways during the 2nd quarter valued at $942,000. Morgan Stanley boosted its stake in COMPASS Pathways by 99.9% during the 2nd quarter. Morgan Stanley now owns 96,730 shares of the company’s stock valued at $3,690,000 after acquiring an additional 48,343 shares during the last quarter. Wells Fargo & Company MN grew its holdings in COMPASS Pathways by 504.8% during the 2nd quarter. Wells Fargo & Company MN now owns 203,586 shares of the company’s stock worth $7,766,000 after acquiring an additional 169,925 shares in the last quarter. Finally, Woodline Partners LP increased its position in shares of COMPASS Pathways by 15.7% in the 2nd quarter. Woodline Partners LP now owns 220,359 shares of the company’s stock worth $8,407,000 after purchasing an additional 29,922 shares during the last quarter. 18.73% of the stock is owned by institutional investors.
About COMPASS Pathways
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.
Featured Article: Strangles
Receive News & Ratings for COMPASS Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COMPASS Pathways and related companies with MarketBeat.com's FREE daily email newsletter.